Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BHE202214

FXR Agonist

BLA Filing
  • Project profile
    Project name: FXR Agonist
    Indications: Diabetic kidney disease
    Research phase: Phase I is ongoing in China
    Cooperation demands: Out licensing global right
  • Highlights

    1. Activation of FXR has an important role in maintaining glucose, lipid, and bile acid homeostasis in the enterohepatic system and preventing rat liver fibrosis as well as atherosclerosis, research showed that FXR agonists have marked renal protective effects. FXR agonists inhibit expression of SREBP-1, ChREBP and SREBP-2, resulting in decreased fatty acid and cholesterol synthesis and accumulation in the kidney.

    2. Oral highly active and highly selective FXR agonist in-vitro, significantly improves diabetic nephropathy at a much lower dose than those of losartan and PX-102.

    3. In vivo, show high absorption rate, high absolute bioavailability, high distribution concentration in kidney, fast clearance and mainly excreted in bile and feces.

  • Project Introduction

    1. Asset type: FXR agonist

    2. Indication: Diabetic kidney disease

    3. Modality: Small molecular

    4. Research phase: Phase I is ongoing in China

    5. Cooperation demands: Out licensing global right

    6. Research progress:

    Phase I clinical research is ongoing in China.

Comments (0)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message